Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.41 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403620 | 0.92 | CHRNA7 (0.39) | CHRNA7CHRNA10CHRNA9KCNH2MEN1 | |
| SCHEMBL13334202 | 0.79 | FFAR1 (0.47) | KCNH2MEN1ALDH1A1POLBMAPT | |
| Bromide SCHEMBL3314057 | 0.77 | FFAR1 (0.46) | CHRNA7CHRNA10CHRNA9KCNH2MEN1 | |
| SCHEMBL4398955 | 0.76 | CHRNA7 (0.64) | CHRNA7CHRNA10CHRNA9KCNH2 | |
| SCHEMBL4399014 | 0.74 | CHRNA7 (0.45) | CHRNA7CHRNA10CHRNA9KCNH2MEN1 | |
| SCHEMBL4400723 | 0.74 | CHRNA7 (0.46) | CHRNA7CHRNA10CHRNA9KMT2A | |
| SCHEMBL13334206 | 0.74 | CHRNA7 (0.59) | CHRNA7CHRNA10CHRNA9KCNH2MEN1 | |
| SCHEMBL12638076 | 0.73 | CHRNA7 (0.51) | CHRNA7CHRNA10CHRNA9KCNH2 | |
| Bromide SCHEMBL3311264 | 0.73 | CHRNA7 (0.60) | CHRNA7CHRNA10CHRNA9KCNH2MEN1 | |
| SCHEMBL4400709 | 0.72 | CHRNA7 (0.50) | CHRNA7CHRNA10CHRNA9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF UTAH (US) | 2016-11-24 | — | — | US | disclosed |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340335-A9 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | CHRNA7 157/4885CHRNA10 126/4885CHRNA9 233/4885 |
| US-20140011836-A1 | METHOD OF TREATING NEUROPATHIC PAIN | INA, GAP43, ACHE | CHRNA7 157/4885CHRNA10 126/4885CHRNA9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.